Beschreibung
Phenytoin, a potent CYP inducer, can increase the metabolism of montelukast, potentially reducing its plasma levels and therapeutic efficacy.
Mechanismus
Phenytoin induces CYP2C8 and CYP3A4, the principal enzymes responsible for montelukast oxidative metabolism, accelerating clearance and reducing AUC.
Klinische Bedeutung
The interaction is predicted based on known enzyme induction by phenytoin; formal pharmacokinetic studies in humans are lacking but CYP induction by phenytoin is well established.
Maßnahmen
Monitor asthma or allergic rhinitis control in patients starting or stopping phenytoin; consider increasing montelukast dose if symptom breakthrough occurs.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.